In Tunisia, this is the first report, which despite the small number of patients, gives a good concordance between molecular and IHC results, emphasizing the interest of setting up targeted IHC, in daily practice, to explore EGFR mutations in small biopsies of lung cancer but should be expanded to clarify relevance of TKIs treatment. This evidence concerns the gene EGFR and lung carcinoma.